Evaluation of the effect of moringa oleifera gel and autologo platelet-rich fibrin in the treatment of rabbit intra bony defects. (Radio graphic and Histological study)

PURPOSE: Periodontitis is the most common condition, which causes bony defects; the ultimate goal of periodontal therapy is the regeneration of the destroyed tissues. There is always a need to search for better biomaterials that can be used for the treatment of intrabony defects. This study evaluated the effect of Moringa oleifera (MO) gel and platelet-rich fibrin (PRF) in the treatment of bone defects. HYPOTHESIS: We hypothesized that MO gel may increase the bone mineral contents and density of bone. METHODS: The study was conducted on 16 defects in 8 adult male rabbits divided into 2 groups; group (1) buccal bone defect treated with moringa hydrogel and PRF (right site), group (2) buccal bone defect treated with PRF (left site). Computed tomography (CT) radiography and histological examination were assessed at baseline, 14 and 28 days. The defects were induced in the form of one osseous wall defect between the 1(st) and the 2(nd) molars. Comparisons between groups were done using an unpaired t-test. For comparison within each group, analysis of variance (ANOVA) was used. RESULTS: CT radiograph results showed there was a significant increase in bone density at 28 days in group 1 than in group 2 (843.13 ± 97.82 to 713.0 ± 51.09). The histological result revealed the defect area on the (PRF + Moringa) was almost filled completely by newly formed bone with few spots of retarded calcification. While (PRF) showed complete filling of the defect area by more fibrous tissue. The healing score showed a significant elevation of bone defect healing score in (PRF + Moringa group) when compared to (PRF group) at both times of evaluation. CONCLUSION: Radiographical examination, and histological and healing scores confirmed the superiority of Moringa + PRF results in an increase in bone fill and density in induced periodontal intrabony defects regeneration. Clinical trials should be considered to detect the effectiveness of MO in intrabony defects.